CD33 and acute myeloid leukemia: Given the flexibility of the RevCAR system to target different tumor entities by easily replacing RevTMs with different specificities, a combinatorial gated approach could be established and successfully used to target CD33 or CD123 on the surface of patient-derived AML blasts.